






psychosocial	 functioning.	 However,	 most	 treatments	 for	 depression	 do	 not	 specifically	 target	
cognition.	Neurocognitive	deficits	such	as	memory	and	concentration	problems	tend	to	persist	after	
mood	symptoms	recover.	Improving	cognition	in	depression	requires	a	better	understanding	of	brain	






psychosocial	 functioning.	At	workplace,	 depression	 is	 one	of	 the	main	 causes	 of	 absenteeism	and	
presenteeism	(Druss	et	al.	2001).	Absenteeism	refers	to	direct	impact	of	depression	on	occupational	
functioning	where	people	cannot	attend	work	due	to	depressive	 illness.	Presenteeism	is	related	to	





residual	 symptoms	 (Conradi	 et	 al.	 2011).	 Numerous	 studies	 reported	 poorer	 neuropsychological	
performance	in	tests	of	memory,	attention	and	executive	function	in	patients	with	depression	(Bora	
et	al.	2013).	Cognitive	dysfunction	in	depression	is	associated	with	poorer	psychosocial	functioning	







The	 “toxicity”	 of	 repeated	 episodes	 (Gorwood	 et	 al.	 2008)	 on	 cognition,	 also	 known	 as	 “scarring”	
(Kessing,	1998)	was	proposed	to	explain	persistence	of	cognitive	dysfunction.	According	to	this,	each	
episode	 leads	 to	 accumulation	 of	 vulnerability,	 hence	 leading	 to	 further	 decline	 in	 cognitive	







reported	significant	 impact	of	cognitive	problems	 in	their	daily	 living	activities.	However,	only	50%	
have	 ever	 been	 asked	 about	 cognitive	 dysfunction	 by	 a	 healthcare	 professional	 (Clark	 Health	
Communications,	2015).	Most	currently	available	treatments	were	shown	to	be	effective	for	overall	
mood	 symptoms,	 whereas	 the	 effects	 on	 cognitive	 functions	 were	 rarely	 tested	 in	 double-blind	
placebo	 controlled	 trials.	 The	 scarcity	 of	 evidence	 on	medication	 effects	 on	 cognitive	 functions	 in	





it	 was	 shown	 that	 8-week	 treatment	 with	 escitalopram,	 sertraline,	 or	 venlafaxine	 did	 not	 have	








a	 large	 randomized	controlled	 trial	 showed	 that	 vortioxetine	 improved	cognitive	 functions	 in	non-
elderly	patients	with	depression	 (McIntyre	et	al.	2014).	Multiple	 regression	analyses	 revealed	 that	
there	was	a	direct	effect	on	cognition	independent	from	the	effects	on	mood.	It	should	be	noted	that	
effect	sizes	for	most	tests	except	digit	symbol	substitution	test	were	small	in	this	study	and	replication	
is	 needed.	 Vortioxetine	 is	 a	 multi-modal	 pharmacological	 agent	 acting	 on	 a	 number	 of	





One	 of	 the	 proposed	 mechanisms	 of	 modafinil’s	 pro-cognitive	 effect	 is	 through	 augmenting	
glutamatergic	 transmission	 in	hippocampus	 (Scoriels	et	 al.	 2013).	Modafinil	 augmentation	 showed	
beneficial	 effects	 on	mood	 and	 fatigue	 (Goss	 &	 Kaser	 et	 al.	 2013)	which	may	make	 its	 use	more	
favourable	for	patients	with	persistent	cognitive	dysfunction.		
	
There	 is	 suggestion	 that	 monoaminergic	 antidepressants	 may	 have	 favourable	 effects	 on	 hot	
(emotion-laden)	cognition.	Antidepressants	were	shown	to	alter	response	biases	to	emotional	stimuli	
very	 early	 in	 the	 course	 of	 treatment	 (Harmer	 et	 al.	 2009).	 The	mechanism	 linking	 this	 effect	 to	
therapeutic	 effects	 is	 yet	 to	 be	 elucidated.	 The	 interplay	 between	 negative	 emotional	 biases	 and	
cognitive	 functions	 in	 depression	 has	 been	 formulated	 in	 cognitive	 neuropsychological	 model.	
According	to	this	model	proposed	by	Roiser,	Elliott	and	Sahakian	(Roiser	et	al.	2012,	Figure	1),	bottom-
up	affective	biases	and	top-down	attentional	biases	(due	to	dysfunctional	cognitive	control)	help	to	







in	 a	 report	 by	 National	 Academy	 of	 Sciences	 (National	 Academies	 of	 Sciences,	 Engineering,	 and	




equally	 important.	 With	 the	 developing	 mobile	 technologies	 and	 more	 accessible	 neurocognitive	
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